Phase II Study on Dose Escalating Schedule of Paclitaxel Concurrent with Radiotherapy in Treating Patients with Locally Advanced Non-small Cell Lung Cancer

Objective: To evaluate clinical efficacy of a dose escalating schedule of paclitaxel concurrent with radiotherapyin treating patients with locally advanced non-small cell lung (NSCLC).
Methods: Patients with locally advancedNSCLC were treated with conventional fractionated radiotherapy or three dimensional conformal radiotherapy(3 DCRT), concurrently with a dose escalating schedule of paclitaxel. All patients were divided into three groups,A with paclitaxel 30 mg/m2, B with paclitaxel 60 mg/m2 and C with paclitaxel 90 mg/m2. Paclitaxel was repeatedevery week for a total of 4 or 6 weeks.
Results: Among 109 patients, response rates were 68.8%, 71.1% and 71.8%(p>0.05) for group A (n=32), B (n=38), and C (n=39) respectively. Accordingly, disease control rates were 81.3%,81.6% and 82.1% (p>0.05). Progression-free survival time was 8.0±5.0 months, 11.6±6.1 months, and 14.8±7.9months (p<0.05), respectively. Overall survival time was 15.4±7.6 months, 18.2±8.0 months, and 22.0±7.6 months(p<0.05), one-year survival rates were 62.5%, 73.1% and 90.0% (p>0.05) and two-year survival rates were 31.3%,38.5% and 50.0% (p<0.05) . Main side-effects were bone marrow suppression, radiation related esophagitis andgastrointestinal reaction.
Conclusion: In treating patients with NSCLC, concurrent chemoradiotherapy withpaclitaxel improves early response compared with conventional fractionated radiotherapy or 3 DCRT. Thesurvival rate was improved with the addition of paclitaxel, but there was an increase in adverse reactions whenthe dose of paclitaxel was increased.